Vmbook Online ordering

Scynexis Inc

Scynexis Inc. is a publicly traded company listed on the Nasdaq stock exchange under the ticker symbol "SCYX."

Here are some key details about the company:

1. Scynexis Inc. is a biotechnology company that focuses on developing innovative therapies for treated fungal infections.

2. The company's lead product candidate is SCY-078, a novel oral and intravenous fungal infection drug.

3. SCY-078 is in Phase 3 clinical trials for the treatment of invasive aspergillosis and Candidemia, serious and potentially life-threatening fungal infections.

4. Scynexis Inc. was founded in 2010, and it is headquartered in Durham, North Carolina.

5. The company has a team of experienced scientists and biotechnology professionals leading its research and development efforts.

Here are some key financial metrics for Scynexis Inc.:

1. Market capitalization: Around $870 million (as of March 2023)

2. Revenue: The company reported $17.3 million in revenue for the third quarter of 2022.

3. Net income: The company recorded a net loss of $11.9 million in the third quarter of 2022.

It is important to note that these figures are subject to change and may have changed since the last public reporting.

The company is worth keeping an eye on, especially with its promising product candidate SCY-078 in Phase 3 clinical trials. However, it is essential to conduct thorough research and analysis before investing in any stock to ensure it aligns with your investment goals and risk tolerance.

I hope this helps! If you have any other questions or need further assistance, feel free to ask.